Press release 10 February 2011

IFPMA supports call for extension of TRIPS compliance deadline for least developed countries

By IFPMA

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) today expressed the research-based pharmaceutical industry’s support for calls to extend the deadline for Least-Developed Countries to comply with the provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).

Mr. David Brennan, President of the IFPMA and CEO of AstraZeneca, said: “We recognize the significant development challenges experienced by Least-Developed Countries and believe that an extension would be useful to allow for effective TRIPS implementation. Such an extension should be used to align implementation across all areas of technology, to ensure a consistent approach. Our industry continues to believe that effective Intellectual Property Rights are a crucial component of long-term economic development within these countries, and international organizations and national bodies should continue to provide technical assistance, based on specific in-country needs.”

Geneva, 10 February 2011

About IFPMA

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.

Learn more

Media Contact

Elliot Dunster
Top